MA50495A - Composés bicycliques à fusion 5,6 et compositions pour le traitement de maladies parasitaires - Google Patents

Composés bicycliques à fusion 5,6 et compositions pour le traitement de maladies parasitaires

Info

Publication number
MA50495A
MA50495A MA050495A MA50495A MA50495A MA 50495 A MA50495 A MA 50495A MA 050495 A MA050495 A MA 050495A MA 50495 A MA50495 A MA 50495A MA 50495 A MA50495 A MA 50495A
Authority
MA
Morocco
Prior art keywords
compositions
treatment
parasitic diseases
fusion compounds
bicyclic
Prior art date
Application number
MA050495A
Other languages
English (en)
Inventor
Jan Jiricek
Isabelle K Lerario
Fang Liang
Xiaodong Liu
Valentina Molteni
Advait Suresh Nagle
Shuyi Pearly Ng
Maxim Ratnikov
Jeffrey M Smith
Yongping Xie
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA50495A publication Critical patent/MA50495A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA050495A 2017-05-31 2018-05-29 Composés bicycliques à fusion 5,6 et compositions pour le traitement de maladies parasitaires MA50495A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762513211P 2017-05-31 2017-05-31
US201762581919P 2017-11-06 2017-11-06

Publications (1)

Publication Number Publication Date
MA50495A true MA50495A (fr) 2021-04-28

Family

ID=62749123

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050495A MA50495A (fr) 2017-05-31 2018-05-29 Composés bicycliques à fusion 5,6 et compositions pour le traitement de maladies parasitaires

Country Status (26)

Country Link
US (2) US11384078B2 (fr)
EP (1) EP3630771B1 (fr)
JP (1) JP7187490B2 (fr)
KR (1) KR20200010275A (fr)
CN (1) CN110678468B (fr)
AR (1) AR111826A1 (fr)
AU (1) AU2018276190B2 (fr)
BR (1) BR112019024804A2 (fr)
CA (1) CA3060990A1 (fr)
CL (1) CL2019003467A1 (fr)
CO (1) CO2019013254A2 (fr)
CR (1) CR20190545A (fr)
CU (1) CU24543B1 (fr)
DO (1) DOP2019000299A (fr)
EC (1) ECSP19084722A (fr)
ES (1) ES2927207T3 (fr)
IL (1) IL270927B (fr)
JO (1) JOP20190278A1 (fr)
MA (1) MA50495A (fr)
MX (1) MX2019014321A (fr)
PE (1) PE20201148A1 (fr)
PH (1) PH12019502652A1 (fr)
RU (1) RU2738647C1 (fr)
TW (1) TW201902894A (fr)
UY (1) UY37745A (fr)
WO (1) WO2018220531A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190278A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
CN115397807A (zh) * 2020-04-17 2022-11-25 帝斯曼知识产权资产管理有限公司 用于制备取代的烯胺化合物的方法
CN113831320B (zh) * 2020-06-23 2024-04-05 上海美悦生物科技发展有限公司 一种稠和吡唑类化合物的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10053275A1 (de) 2000-10-27 2002-05-02 Dresden Arzneimittel Neue 7-Azaindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
DE602004029145D1 (de) 2003-02-27 2010-10-28 Palau Pharma Sa Pyrazolopyridin-derivate
AR085410A1 (es) 2011-02-25 2013-10-02 Dow Agrosciences Llc Derivados de pirazol heteroaril-sustituidos, composiciones pesticidas que los comprenden y su uso en el control de plagas
WO2013067302A1 (fr) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Méthode de traitement
WO2013106254A1 (fr) 2012-01-11 2013-07-18 Dow Agrosciences Llc Compositions pesticides et procédés qui leur sont associés
ME03042B (fr) 2012-11-19 2018-10-20 Novartis Ag Composés et compositions pour le traitement de maladies parasitaires
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
WO2014151729A1 (fr) 2013-03-15 2014-09-25 Irm Llc Composés et compositions pour le traitement de maladies parasitaires
MA39186A1 (fr) * 2013-12-19 2017-11-30 Novartis Ag Dérivés de [1,2,4]triazolo[1,5-a]pyrimidine utilisés comme inhibiteurs du protéasome des protozoaires pour le traitement de maladies parasitaires comme la leishmaniose
JP2017537914A (ja) 2014-12-02 2017-12-21 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 有害生物防除剤としての二環式化合物
WO2016144351A1 (fr) 2015-03-11 2016-09-15 E. I. Du Pont De Nemours And Company Pesticides à base d'azole bicyclique substitué par hétérocycle
AU2016269626B2 (en) 2015-05-29 2019-05-30 Glaxosmithkline Intellectual Property Development Limited Imidazo[1,2-b][1,2,4]triazine derivatives as antiparasitic agents
EP3331885B1 (fr) 2015-08-07 2020-12-23 GlaxoSmithKline Intellectual Property Development Limited Composés
KR102388962B1 (ko) 2016-05-03 2022-04-27 바이엘 파마 악티엔게젤샤프트 방향족 술폰아미드 유도체
JOP20190278A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية

Also Published As

Publication number Publication date
UY37745A (es) 2019-01-02
ECSP19084722A (es) 2019-12-27
TW201902894A (zh) 2019-01-16
JOP20190278A1 (ar) 2019-11-28
PE20201148A1 (es) 2020-10-26
KR20200010275A (ko) 2020-01-30
ES2927207T3 (es) 2022-11-03
CL2019003467A1 (es) 2020-03-13
CA3060990A1 (fr) 2018-12-06
EP3630771B1 (fr) 2022-06-29
MX2019014321A (es) 2020-02-05
CR20190545A (es) 2020-01-15
CU24543B1 (es) 2021-08-06
US20200109142A1 (en) 2020-04-09
BR112019024804A2 (pt) 2020-06-09
IL270927A (en) 2020-01-30
CO2019013254A2 (es) 2020-01-17
IL270927B (en) 2022-01-01
DOP2019000299A (es) 2019-12-15
EP3630771A1 (fr) 2020-04-08
AU2018276190A1 (en) 2019-11-07
RU2738647C1 (ru) 2020-12-15
JP2020521775A (ja) 2020-07-27
PH12019502652A1 (en) 2020-07-13
JP7187490B2 (ja) 2022-12-12
WO2018220531A1 (fr) 2018-12-06
US11384078B2 (en) 2022-07-12
CU20190095A7 (es) 2020-10-20
US20220324863A1 (en) 2022-10-13
AU2018276190B2 (en) 2020-05-14
CN110678468B (zh) 2022-07-29
CN110678468A (zh) 2020-01-10
AR111826A1 (es) 2019-08-21

Similar Documents

Publication Publication Date Title
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA55974A (fr) Composés triaryles pour le traitement de maladies pd-l1
MA55325A (fr) Composés pour le traitement de maladies pd-l1
MA49767A (fr) Conjugués de cytokine pour le traitement de maladies auto-immunes
MA51673A (fr) Composés destinés au traitement de troubles dépendant de la kinase
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
MX2018013472A (es) Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares.
MA46228A (fr) Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
MA53835A (fr) Lactams bicycliques en tant qu'inhibiteurs de la protéine kinase 1 interagissant avec des récepteurs pour le traitment p.e. de maladies inflammatoires
MA51916A (fr) Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
MA54229A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
MA47719A (fr) Esketamine pour le traitement de la dépression
MA45089A (fr) Utilisation d'indazoles 2-substitués pour le traitement et la prophylaxie de maladies auto-immunes
MA42953A (fr) Composés et compositions pour le traitement de troubles oculaires
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
MA54515A (fr) Dérivés de quinoléine destinés à être utilisés dans le traitement de maladies inflammatoires
WO2018067520A3 (fr) Procédés et agents thérapeutiques
MA51738A (fr) Composés pour le traitement de la douleur
DK3720433T3 (da) Bis-cholin-tetrathiomolybdat til behandling af wilsons sygdom
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA46099A (fr) Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
MA55148A (fr) Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance